Yi-Xi He

Assessing persistent antitumor immunity induced by tumor derived extracellular vesicle hydrogel vaccination without neoantigen identification.

Personalized cancer vaccines show great promise in targeting tumors with immunity; however, obstacles to their widespread use in clinical practice remain, including difficulties in identifying neoantigens, slow antigen clearance, and inadequate removal of tumor cells expressing the antigen. Here, we present a hydrogel...